{"url":"https://lda.gov/api/v1/filings/9907f4ca-5c2d-4ccf-9b80-7fe4f1c48bfd/","filing_uuid":"9907f4ca-5c2d-4ccf-9b80-7fe4f1c48bfd","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/9907f4ca-5c2d-4ccf-9b80-7fe4f1c48bfd/print/","filing_document_content_type":"text/html","income":null,"expenses":"1420000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Peter Norman","dt_posted":"2025-04-18T10:00:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"900 Winter Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Waltham","registrant_state":"MA","registrant_zip":"02451","registrant":{"id":400458235,"url":"https://lda.gov/api/v1/registrants/400458235/","house_registrant_id":null,"name":"ALKERMES, INC.","description":"Biopharmaceutical company","address_1":"900 Winter Street","address_2":null,"address_3":null,"address_4":null,"city":"Waltham","state":"MA","state_display":"Massachusetts","zip":"02451","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PETER NORMAN","contact_telephone":"+1 202-494-6142","dt_updated":"2026-07-29T09:53:25.972881-04:00"},"client":{"id":191188,"url":"https://lda.gov/api/v1/clients/191188/","client_id":12,"name":"ALKERMES, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2012-04-20"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase-in for small companies;","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":59479,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"NORMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148230,"prefix":"mr","prefix_display":"MR.","first_name":"ZACHARY","nickname":null,"middle_name":"MICHAEL","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107279,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":"PATRICK","last_name":"HIBBS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":59479,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"NORMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148230,"prefix":"mr","prefix_display":"MR.","first_name":"ZACHARY","nickname":null,"middle_name":"MICHAEL","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107279,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":"PATRICK","last_name":"HIBBS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Expand funding and flexibility to address all substance use disorders;","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":59479,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"NORMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148230,"prefix":"mr","prefix_display":"MR.","first_name":"ZACHARY","nickname":null,"middle_name":"MICHAEL","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107279,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":"PATRICK","last_name":"HIBBS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}